Biotech Values

[DewDiligence]

genisi’s post about Copaxone’s pharmacokinetic properties is an almost verbatim copy of Teva’s talking points. This doesn’t necessarily mean that genisi’s post is wrong, but it’s not necessarily right either. What is patently clear is that Teva has been waging a vigorous propaganda campaign in the investment community with respect to the prospects for generic Copaxone.